BioNTech (BNTX) Q1 FY26 earnings call: guidance and Q&A

Rationale for changing the primary endpoint from dual PFS/OS to single PFS for the RecetaLANg-02 trial, including discussions with BMS and FDA.

The change was made because PFS is a well-accepted endpoint in non-small cell lung cancer, expected to show the largest and earliest benefit. Allocating the full alpha to PFS ensures a statistically robust readout. OS remains a key secondary endpoint, and this regulatory path is well-trodden, allowing for approval even with delayed OS data.

“We have made this change because PFS is a well-accepted endpoint in non-small cell lung cancer and is very large, and we expect the largest and earliest benefit a signal in this endpoint and wanted to make sure that we allocate the full alpha on this endpoint and have a statistically robust read out.”

asked by Daina Graybosch · answered by Özlem Türeci

How TPAM's data in the HR-positive HER2-low breast cancer trial (Dynasty BREAST 02) is expected to differentiate from Enhertu.

The primary endpoint is objective response rate in connection with duration of response. TPAM has shown clinically meaningful benefit in lower HER2 populations (1+ and 2+), which is a differentiator. While there's no direct comparison to Enhertu, physicians desire more options. TPAM is also considered a strategic asset for building BioNTech's commercial engine and as a combination partner.

“The differentiation is that we have now a data set, which shows that our ADC has also a clinically meaningful benefit in the lower HER2 population and the 1-plus and 2-plus population, which is a differentiator.”

asked by Jessica Fye · answered by Özlem Türeci

If recent HARMONY 3 PFS interim data changes assumptions for Ocotlan trials, and if chemo combos are still the optimal market entry given HARMONY 3's OS HR of 0.6.

The HARMONY 3 interim PFS data is statistically uninformative due to the use of minimal alpha, so it does not change BioNTech's overall strategy. BioNTech's strategy includes Pumitamig monotherapy and ADC combinations, with over 10 clinical trials ongoing for Pumitamig + ADC combinations, with initial data expected in H2 2026.

“However, Summit management has signaled that quote, they have deliberately used in minimal alpha to set the bar high, which is a very valid approach at that in this case. However, it also means that statistically this interim analysis is uninformative on the hazard ratio.”

asked by Manoj Eradath · answered by Özlem Türeci

Updated thoughts on capital deployment given substantial cash, rationale for the $1 billion share buyback, and revenue progression for FY26 given Q1 seasonality.

Capital allocation remains focused on pipeline investment, commercial build-out, and M&A flexibility. The $1 billion buyback is opportunistic, reflecting confidence, and complements R&D without compromising pipeline. FY26 revenue guidance is reaffirmed, assuming lower COVID-19 vaccine revenues and similar seasonal pacing to last year, with the majority of revenue expected in the last four months.

“So the repurchasing program is not at the expense of our innovation efforts on pipeline, but it's more to be seen as an element of our overall capital allocation strategy.”

asked by Asad Haider · answered by Ramón Zapata-Gomez

If competitor bispecific data (HARMONY 6) showing a clear OS benefit changes the bar for RecetaLANg, and what would be considered a strong OS trend.

The competitor data (HARMONY 6) is from a China study with a different comparator (titles past chemo vs. pembrolizumab chemo), so it would not have a direct impact on RecetaLANg-02.

“Remind you that this is a China study, which means that the comparator is titles past chemo, not embolus chemo. So it would not have a direct full for our [indiscernible] study.”

asked by Unknown Analyst · answered by Özlem Türeci